German firm shelves libido-boosting drug for women

Oct 09, 2010

German drug firm Boehringer Ingelheim has shelved development of a libido-booster for women after it was given the thumbs down by the US Food and Drug Administration (FDA), the company said.

"The response of the authorities and the complexity and extent of further questions that would need to be addressed to potentially obtain registration for flibanserin have impacted the company's decision to focus on other pipeline projects," Boehringer said in the statement published on its website.

Originally intended as an anti-depressant, the drug flibanserin -- in the form of a pink pill -- began being tested years ago as a potential libido aid after women said it failed to fight the blues but did boost their sex drive.

Lack of desire is the most common sexual problem in women aged 30 to 60, just as erectile dysfunction is the most common sexual disorder among men in the same age bracket, researchers said.

Clinical trials to test flibanserin's efficacy in raising the level of sexual desire in women were held in Canada, Europe and the United States.

The FDA said in June that two US trials with the drug and a placebo "both failed to demonstrate a statistically significant improvement on the co-primary endpoint of sexual desire."

"Therefore, neither study met the agreed-upon criteria for success in establishing the efficacy of flibanserin for the treatment of HSDD ()," the administration added.

Besides the inconclusive results, the FDA noted the drug in some patients caused side effects including depression and dizziness.

The US Reproductive Health Drugs Advisory Committee also said that the efficacy and safety of flibanserin had not been determined.

Boehringer Ingelheim has been researching flibanserin as a treatment for post-menopausal HSDD in women since the popular Viagra for men hit the market in 1998.

The potential market for a libido booster for women has been estimated by some analysts at around two billion dollars.

Flibanserin belongs to a family of anti-depressants that acts on the body's level of serotonin, a molecule that plays a role in mood changes.

Boehringer Ingelheim said that "the company continues to believe in the value that flibanserin would have for women suffering with HSDD, a significant and recognised medical condition which impacts the lives of many women around the world."

"The decision was not made lightly, considering the advanced stage of development," board chairman Andreas Barner was quoted as saying.

"We remain convinced of the positive benefit-risk ratio of flibanserin for suffering with HSDD."

Boehringer Ingelheim said it would reallocate resources to other areas, such as stroke prevention, diabetes and cancer.

Explore further: Feds vows to publicize vaccine injury help program

add to favorites email to friend print save as pdf

Related Stories

FDA: 'Female Viagra' falls short

Jun 16, 2010

(AP) -- The first pill designed to boost the female sex drive failed to make a significant impact on libido in two studies, federal health regulators said, though some women did report slightly more sexually ...

Testosterone patch benefits women with low sexual desire

Aug 14, 2007

Novel research published in the current issue of The Journal of Sexual Medicine supports the claim that women with hypoactive sexual desire disorder or HSDD (persistent or recurrent deficiency and/or absence of sexual fanatasies/thoughts, ...

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

Roj
not rated yet Oct 09, 2010
Boehringer said it would reallocate resources to other areas
Resources for lawmakers & elections get the FDA to swallow all kinds of Snake oil from domestic-pharmaceutical lobbyists.

See the pharmaceutical litigation industry
https://encrypted...la:en-US

See 2010 recalls of Aromatase Inhibitors
http://www.usreca...-recalls

Boerhiringer Ingelheim may be the last trustworthy prescription a doctor can make, since it clearly refused to access corrupt-Governments, lobby, finance elections, or otherwise push doctor prescriptions with marketing blitz.
junkd
not rated yet Nov 22, 2010

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.